Impact of COVID-19 on gynecological cancer incidence: a large cohort study in Japan

[1] Komatsu H(2023)Impact of the COVID-19 pandemic on surgery for benign diseases in gynecology: a nationwide survey by the Japan Society of Obstetrics and Gynecology J Obstet Gynaecol Res 49 314-320

[2] Nakagawa S(2022)Impact of COVID-19 on cervical cancer screening in Japan: a survey of population-based screening in urban Japan by the Japan Society of Gynecologic Oncology J Obstet Gynaecol Res 48 757-765

[3] Yamagami W(2022)Impact of COVID-19 on gynecologic cancer treatment in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO) J Gynecol Oncol 33 2340-2366

[4] Nogami Y(2020)ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies ESMO Open 5 129-135

[5] Makabe T(2017)ESMO-magnitude of clinical benefit scale version 1.1 Ann Oncol 28 1054-1058

[6] Komatsu H(2019)Revised FIGO staging for carcinoma of the cervix uteri Int J Gynaecol Obstet 145 1303-undefined

[7] Nogami Y(2021)Re-classification of uterine cervical cancer cases treated with radical hysterectomy based on the 2018 FIGO staging system Taiwan J Obstet Gynecol 60 undefined-undefined

[8] Komatsu H(2022)Impact of coronavirus disease 2019 on the number of newly diagnosed cancer patients and examinations and surgeries performed for cancer in Japan: A nationwide study BMC Cancer 22 undefined-undefined

[9] Makabe T(2023)Changes in colorectal cancer treatment during the COVID-19 pandemic in Japan: Interrupted time-series analysis using the National Database of Japan Cancer Epidemiol 85 undefined-undefined

[10] Colombo I(2023)The impact of early-stage COVID-19 pandemic on the diagnosis and treatment of gastric cancer: A cross-sectional study using a large-scale cancer registry in Hiroshima Japan DEN Open 3 undefined-undefined

[1] Komatsu H(2023)Impact of the COVID-19 pandemic on surgery for benign diseases in gynecology: a nationwide survey by the Japan Society of Obstetrics and Gynecology J Obstet Gynaecol Res 49 314-320

[2] Nakagawa S(2022)Impact of COVID-19 on cervical cancer screening in Japan: a survey of population-based screening in urban Japan by the Japan Society of Gynecologic Oncology J Obstet Gynaecol Res 48 757-765

[3] Yamagami W(2022)Impact of COVID-19 on gynecologic cancer treatment in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO) J Gynecol Oncol 33 2340-2366

[4] Nogami Y(2020)ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies ESMO Open 5 129-135

[5] Makabe T(2017)ESMO-magnitude of clinical benefit scale version 1.1 Ann Oncol 28 1054-1058

[6] Komatsu H(2019)Revised FIGO staging for carcinoma of the cervix uteri Int J Gynaecol Obstet 145 1303-undefined

[7] Nogami Y(2021)Re-classification of uterine cervical cancer cases treated with radical hysterectomy based on the 2018 FIGO staging system Taiwan J Obstet Gynecol 60 undefined-undefined

[8] Komatsu H(2022)Impact of coronavirus disease 2019 on the number of newly diagnosed cancer patients and examinations and surgeries performed for cancer in Japan: A nationwide study BMC Cancer 22 undefined-undefined

[9] Makabe T(2023)Changes in colorectal cancer treatment during the COVID-19 pandemic in Japan: Interrupted time-series analysis using the National Database of Japan Cancer Epidemiol 85 undefined-undefined

[10] Colombo I(2023)The impact of early-stage COVID-19 pandemic on the diagnosis and treatment of gastric cancer: A cross-sectional study using a large-scale cancer registry in Hiroshima Japan DEN Open 3 undefined-undefined